Published in J Virol on February 01, 1992
Replication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays. J Virol (1995) 2.63
The minimal replicator of Epstein-Barr virus oriP. J Virol (2000) 1.75
The plasmid replicon of EBV consists of multiple cis-acting elements that facilitate DNA synthesis by the cell and a viral maintenance element. EMBO J (1998) 1.73
Sequence requirements of the Epstein-Barr virus latent origin of DNA replication. J Virol (1994) 1.64
Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1. J Virol (2002) 1.58
Constitutive binding of EBNA1 protein to the Epstein-Barr virus replication origin, oriP, with distortion of DNA structure during latent infection. EMBO J (1993) 1.53
EBNA-1, the major nuclear antigen of Epstein-Barr virus, resembles 'RGG' RNA binding proteins. EMBO J (1994) 1.29
Human RPA (hSSB) interacts with EBNA1, the latent origin binding protein of Epstein-Barr virus. Nucleic Acids Res (1998) 1.23
Rep*: a viral element that can partially replace the origin of plasmid DNA synthesis of Epstein-Barr virus. J Virol (1998) 1.15
Cooperative assembly of EBNA1 on the Epstein-Barr virus latent origin of replication. J Virol (1996) 1.08
Easily unwound DNA sequences and hairpin structures in the Epstein-Barr virus origin of plasmid replication. J Virol (1993) 0.99
Effect of number and position of EBNA-1 binding sites in Epstein-Barr virus oriP on the sites of initiation, barrier formation, and termination of replication. J Virol (1993) 0.96
Epstein-Barr nuclear antigen 1 binds and destabilizes nucleosomes at the viral origin of latent DNA replication. Nucleic Acids Res (2001) 0.96
The replicator of the Epstein-Barr virus latent cycle origin of DNA replication, oriP, is composed of multiple functional elements. J Virol (2001) 0.91
The Epstein-Barr Virus EBNA1 Protein. Scientifica (Cairo) (2012) 0.85
Epstein-Barr virus (EBV) nuclear antigen 1 colocalizes with cellular replication foci in the absence of EBV plasmids. J Virol (2003) 0.84
Epstein-Barr nuclear antigen 1 (EBNA1)-dependent recruitment of origin recognition complex (Orc) on oriP of Epstein-Barr virus with purified proteins: stimulation by Cdc6 through its direct interaction with EBNA1. J Biol Chem (2012) 0.83
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
A new method for sequencing DNA. Proc Natl Acad Sci U S A (1977) 250.51
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology (1973) 127.36
Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol (1967) 106.91
Measurement of protein using bicinchoninic acid. Anal Biochem (1985) 74.03
Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A (1985) 68.48
DNAse footprinting: a simple method for the detection of protein-DNA binding specificity. Nucleic Acids Res (1978) 30.43
DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 27.05
Predicting DNA duplex stability from the base sequence. Proc Natl Acad Sci U S A (1986) 21.73
Affinity purification of sequence-specific DNA binding proteins. Proc Natl Acad Sci U S A (1986) 14.92
Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature (1985) 14.39
Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A (1973) 12.70
A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A (1984) 10.91
CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA). Lancet (1964) 9.32
A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. Mol Cell Biol (1985) 7.66
Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell (1985) 7.17
A one-step purification of membrane proteins using a high efficiency immunomatrix. J Biol Chem (1982) 6.70
A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol Cell Biol (1985) 6.44
Duplex opening by dnaA protein at novel sequences in initiation of replication at the origin of the E. coli chromosome. Cell (1988) 6.42
trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol (1986) 6.00
Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line. J Virol (1980) 5.59
Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci U S A (1980) 5.02
One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. Proc Natl Acad Sci U S A (1983) 4.94
Binding and unwinding--how T antigen engages the SV40 origin of DNA replication. Cell (1990) 4.65
An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology (1975) 4.48
Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells. J Virol (1991) 4.46
Transcriptional elements as components of eukaryotic origins of DNA replication. Cell (1988) 4.43
Footprinting DNA-protein complexes in situ following gel retardation assays using 1,10-phenanthroline-copper ion: Escherichia coli RNA polymerase-lac promoter complexes. Biochemistry (1987) 4.16
The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication. Cell (1989) 4.16
Trace polypeptides in cellular extracts and human body fluids detected by two-dimensional electrophoresis and a highly sensitive silver stain. Proc Natl Acad Sci U S A (1979) 4.11
Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells. Mol Cell Biol (1985) 4.03
Localized melting and structural changes in the SV40 origin of replication induced by T-antigen. EMBO J (1988) 3.96
DNA supercoiling promotes formation of a bent repression loop in lac DNA. J Mol Biol (1987) 3.81
High level expression of nonfused foreign genes with Autographa californica nuclear polyhedrosis virus expression vectors. Virology (1989) 3.31
Isolation of human sequences that replicate autonomously in human cells. Mol Cell Biol (1989) 3.16
Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus. J Virol (1989) 3.15
The ease of DNA unwinding as a determinant of initiation at yeast replication origins. Cell (1988) 2.95
Specialized nucleoprotein structures at the origin of replication of bacteriophage lambda: localized unwinding of duplex DNA by a six-protein reaction. Proc Natl Acad Sci U S A (1986) 2.79
Functional domains of Epstein-Barr virus nuclear antigen EBNA-1. J Virol (1991) 2.63
Interaction of the lymphocyte-derived Epstein-Barr virus nuclear antigen EBNA-1 with its DNA-binding sites. J Virol (1989) 2.36
Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in Epstein-Barr virus DNA. J Virol (1990) 2.35
Initiation protein induced helix destabilization at the lambda origin: a prepriming step in DNA replication. Cell (1988) 2.24
Three domains in the simian virus 40 core origin orchestrate the binding, melting, and DNA helicase activities of T antigen. J Virol (1990) 2.24
Rapid "footprinting" on supercoiled DNA. Proc Natl Acad Sci U S A (1985) 2.21
Enhancer-origin interaction in plasmid R6K involves a DNA loop mediated by initiator protein. Cell (1988) 2.21
Host cell regulation of induction of Epstein-Barr virus. J Virol (1974) 2.19
Overproduction, purification, and characterization of EBNA1, the origin binding protein of Epstein-Barr virus. J Biol Chem (1991) 2.06
Helicase action of dnaB protein during replication from the Escherichia coli chromosomal origin in vitro. J Biol Chem (1987) 2.00
Replication of plasmids derived from bovine papilloma virus type 1 and Epstein-Barr virus in cells in culture. Annu Rev Cell Biol (1987) 1.93
Functional limits of oriP, the Epstein-Barr virus plasmid origin of replication. J Virol (1989) 1.82
Identification of Epstein-Barr virus sequences that encode a nuclear antigen expressed in latently infected lymphocytes. Proc Natl Acad Sci U S A (1984) 1.66
Herpes simplex virus origin-binding protein (UL9) loops and distorts the viral replication origin. J Virol (1991) 1.62
Possible role for thymine glycol in the selective inhibition of DNA synthesis on oxidized DNA templates. Cancer Res (1985) 1.46
Differential induction of structural changes in the simian virus 40 origin of replication by T antigen. J Virol (1991) 1.30
High-resolution footprints of the DNA-binding domain of Epstein-Barr virus nuclear antigen 1. Mol Cell Biol (1989) 1.18
Electron microscopic evidence for replication of circular Epstein-Barr virus genomes in latently infected Raji cells. J Virol (1984) 1.18
Structure of the Epstein-Barr virus nuclear antigen as probed with monoclonal antibodies. Virology (1985) 0.87
Inhibition of specific binding of EBNA 1 to DNA by murine monoclonal and certain human polyclonal antibodies. Virology (1990) 0.80
Single-stranded structures are present within plasmids containing the Epstein-Barr virus latent origin of replication. J Virol (1991) 0.78
Stem cell patterning and fate in human epidermis. Cell (1995) 5.22
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology (1999) 4.13
Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia (2005) 2.09
Isolated microscopic haematuria in the genitourinary clinic: the value of renal biopsy. Int J STD AIDS (1997) 2.02
Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med (1996) 1.74
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Systematic analysis of peptide recoveries from in-gel digestions for protein identifications in proteome studies. J Biomol Tech (2000) 1.64
Clinical presentation of inhalational anthrax following bioterrorism exposure: report of 2 surviving patients. JAMA (2001) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Cognitive demand and blood glucose. Physiol Behav (2001) 1.18
First observation of the decay Bs0-->Ds-Ds+ and measurement of its branching ratio. Phys Rev Lett (2008) 1.11
Signal transducer and activator of transcription 6 (STAT-6) expression and function in asthmatic bronchial epithelium. J Allergy Clin Immunol (2001) 1.11
Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther (2003) 1.11
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett (2012) 1.09
Search for supersymmetry at the LHC in events with jets and missing transverse energy. Phys Rev Lett (2011) 1.08
Measurement of sigma chi c2 B(chi c2-->J/psi gamma)/sigma chi c1 B(chi c1 -->J/psi gamma) in pp collisions at square root s=1.96 TeV. Phys Rev Lett (2007) 1.07
Search for stopped Gluinos in pp collisions at square root s=7 TeV. Phys Rev Lett (2011) 1.07
Measurement of the Υ1S, Υ2S, and Υ3S polarizations in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2013) 1.05
Direct measurement of the W production charge asymmetry in pp collisions at square root s=1.96 TeV. Phys Rev Lett (2009) 1.04
Search for long-lived massive charged particles in 1.96 TeV pp collisions. Phys Rev Lett (2009) 1.03
Spontaneous burrowing behaviour in the rat is reduced by peripheral nerve injury or inflammation associated pain. Eur J Pain (2012) 1.02
A rapid method for semi-quantitative analysis of neurite outgrowth from chick DRG explants using image analysis. J Neurosci Methods (1999) 1.01
Observation of Bs(0)-Bs(0) oscillations. Phys Rev Lett (2006) 1.00
Measurement of the polarization of W bosons with large transverse momenta in W + jets events at the LHC. Phys Rev Lett (2011) 0.99
RS cyclophilins: identification of an NK-TR1-related cyclophilin. Gene (1996) 0.99
Measurement of the inclusive jet cross section in pp collisions at √s = 7 TeV. Phys Rev Lett (2011) 0.98
Search for neutral minimal supersymmetric standard model Higgs bosons decaying to tau pairs in pp collisions at √s=7 TeV. Phys Rev Lett (2011) 0.97
Search for large extra dimensions in final states containing one photon or jet and large missing transverse energy produced in pp collisions at square root[s]=1.96 TeV. Phys Rev Lett (2008) 0.97
Polarizations of J/psi and psi(2S) mesons produced in pp collisions at square root s = 1.96 TeV. Phys Rev Lett (2007) 0.96
Measurement of the top-quark mass in all-hadronic decays in pp collisions at CDF II. Phys Rev Lett (2007) 0.95
Colorectal carcinogenesis: sequential steps in the in vitro immortalization and transformation of human colonic epithelial cells (review). Anticancer Res (1990) 0.95
Measurement of associated production of vector bosons and top quark-antiquark pairs in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2013) 0.95
Search for dark matter and large extra dimensions in pp collisions yielding a photon and missing transverse energy. Phys Rev Lett (2012) 0.95
Expansion of the kidney donor pool by using cardiac death donors with prolonged time to cardiorespiratory arrest. Am J Transplant (2011) 0.94
Turbidity dynamics during spring storm events in an urban headwater river system: the Upper Tame, West Midlands, UK. Sci Total Environ (2006) 0.93
Search for a fermiophobic Higgs boson decaying into diphotons in pp[over] collisions at sqrt[s] = 1.96 TeV. Phys Rev Lett (2009) 0.92
First measurement of Bose-Einstein correlations in proton-proton collisions at √s=0.9 and 2.36 TeV at the LHC. Phys Rev Lett (2010) 0.91
First measurement of the b-jet cross section in events with a W boson in pp collisions at square root(s) = 1.96 TeV. Phys Rev Lett (2010) 0.91
Spectrum of quality of life impairment in hypothyroidism. Qual Life Res (1994) 0.91
Search for Z' --> e+ e- using dielectron mass and angular distribution. Phys Rev Lett (2006) 0.90
Search for supersymmetry in pp collisions at √7 TeV in events with two photons and missing transverse energy. Phys Rev Lett (2011) 0.90
The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease. Xenobiotica (2010) 0.89
Evidence for a separate meal-associated oscillator in the rat. Physiol Behav (1982) 0.89
Socio-economic inequalities and oral health in Canada and the United States. J Dent Res (2012) 0.89
Inequalities in cancer survival and the NHS cancer plan: evidence of progress? Br J Cancer (2010) 0.87
Search for top-quark production via flavor-changing neutral currents in W+1 jet events at CDF. Phys Rev Lett (2009) 0.87
Inequalities of health indicators for policy makers: six hints. Int J Public Health (2012) 0.87
Effect of increasing doses of beta agonists on spirometric parameters, exercise capacity, and quality of life in patients with chronic airflow limitation. Thorax (1994) 0.87
Inclusive search for squark and gluino production in pp[over ] collisions at sqrt[s]=1.96 TeV. Phys Rev Lett (2009) 0.87
Search for the flavor-changing neutral-current decay t-->Zq in pp collisions at sqrt[s] = 1.96 TeV. Phys Rev Lett (2008) 0.86
Search for pair production of second-generation scalar leptoquarks in pp collisions at √s = 7 TeV. Phys Rev Lett (2011) 0.86
Measurement of the B(+) production cross section in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2011) 0.86
Search for anomalous production of multilepton events in pp collisions at sqrt s=1.96 TeV. Phys Rev Lett (2007) 0.86
Measurement of the B0 production cross section in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2011) 0.85
Search for new high-mass particles decaying to Lepton pairs in pp collisions at square root s = 1.96 TeV. Phys Rev Lett (2005) 0.85
Search for three-jet resonances in pp collisions at square root(s)=7 TeV. Phys Rev Lett (2011) 0.85
Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase. Xenobiotica (2006) 0.84
Observation of sequential Υ suppression in PbPb collisions. Phys Rev Lett (2012) 0.84
The "Americanisation" of migrants: evidence for the contribution of ethnicity, social deprivation, lifestyle and life-course processes to the mid-20th century Coronary Heart Disease epidemic in the US. Soc Sci Med (2006) 0.83
Effects of arterial pressure in an experimental isolated haemoperfused porcine kidney preservation system. Br J Surg (2006) 0.83
Analysis of the quantum numbers J(PC) of the X(3872) particle. Phys Rev Lett (2007) 0.83
Search for Higgs bosons predicted in two-Higgs-doublet models via decays to tau lepton pairs in 1.96 TeV pp collisions. Phys Rev Lett (2009) 0.83
Search for supersymmetry in pp collisions at sqrt[s]=1.96 TeV Using the trilepton signature for chargino-neutralino production. Phys Rev Lett (2008) 0.83
Search for the production of narrow tb[over] resonances in 1.9 fb;{-1} of pp[over] collisions at sqrt[s] = 1.96 TeV. Phys Rev Lett (2009) 0.82
Forward-backward asymmetry in top-quark production in pp[over] collisions at sqrt[s]=1.96 TeV. Phys Rev Lett (2008) 0.82
Search for neutral Higgs bosons of the minimal supersymmetric standard model decaying to tau pairs in pp collisions at square root of s = 1.96 TeV. Phys Rev Lett (2006) 0.82
Search for [corrected] B0(s) --> mu+ mu- and B0(d) [corrected] --> mu + mu- decays in pp collisions with CDF II. Phys Rev Lett (2005) 0.81
Study of Z Boson Production in PbPb Collisions at √S(NN)=2.76 TeV. Phys Rev Lett (2011) 0.81
Effect of telephone followups on post vasectomy office visits. Urol Nurs (2000) 0.81
Precision top-quark mass measurement in the lepton+jets topology in p p collisions at square root s=1.96 TeV. Phys Rev Lett (2006) 0.81
Dijet azimuthal decorrelations in pp collisions at √s=7 TeV. Phys Rev Lett (2011) 0.80
Search for B(s)(0) → μ+ μ- and B(0) → μ+ μ- decays in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2011) 0.80
Observation of electroweak single top-quark production. Phys Rev Lett (2009) 0.80
Search for heavy neutrinos and W(R) bosons with right-handed couplings in a left-right symmetric model in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 0.80
Pharmacoeconomic viewpoints on volatile anaesthesia--"much ado about nothing?". Anaesth Intensive Care (2005) 0.80
Google governance: increasing the effectiveness of critical care physicians through the use of an online usergroup. Emerg Med J (2010) 0.79
Origin and structure of pathogenic IgA in IgA nephropathy. Biochem Soc Trans (1997) 0.78
Nonatopic allergen-independent mast cell activation in parasitized eosinophilic athymic rats. Parasite Immunol (2005) 0.78
Localization of nerve growth factor (NGF) and low-affinity NGF receptors in touch domes and quantification of NGF mRNA in keratinocytes of adult rats. J Comp Neurol (1994) 0.78
The staurosporine-like compound L-753,000 (NB-506) potentiates the neurotrophic effects of neurotrophin-3 by acting selectively at the TrkA receptor. Mol Pharmacol (1999) 0.77
Microscopic haematuria. Role of renal biopsy is undervalued. BMJ (1994) 0.77
The effect of increasing doses of beta-agonists on airflow in patients with chronic airflow limitation. Respir Med (1993) 0.77
Subcapsular haematoma: a cause of post biopsy oliguria in renal allografts. Nephrol Dial Transplant (2000) 0.77
First flavor-tagged determination of bounds on mixing-induced CP violation in Bs0 --> J/psiphi decays. Phys Rev Lett (2008) 0.77
Computer-task testing of rhesus monkeys (Macaca mulatta) in the social milieu. Primates (1994) 0.77
Cholinergic elements in a human choriocarcinoma cell line. Biochem Pharmacol (1981) 0.77
Measurement of the top-quark mass with dilepton events selected using neuroevolution at CDF. Phys Rev Lett (2009) 0.77
Measurement of the Bs0-Bs0 oscillation frequency. Phys Rev Lett (2006) 0.77
Failure of bovine complement levels measured by radial hemolysis to correlate with tube titration. Am J Vet Res (1983) 0.77
cDNA sequence of the human erythroid alpha-spectrin: identification of a base deletion in the sequence database. Blood (1999) 0.76
Observation of orbitally excited B(s) mesons. Phys Rev Lett (2008) 0.76
A rapid method for determination of cell survival in primary neuronal DRG cultures. J Neurosci Methods (1999) 0.76
Observation of B(s)0-->K+ K- and measurements of branching fractions of charmless two-body decays of B0 and B(s)0 mesons in pp collisions at square root of s = 1.96 TeV. Phys Rev Lett (2006) 0.76
Search for charged Higgs bosons in decays of top quarks in pp collisions at square root s = 1.96 TeV. Phys Rev Lett (2009) 0.76
Observation of a new Ξb baryon. Phys Rev Lett (2012) 0.76